STADA, the parent company of Huddersfield-based Thornton & Ross (T&R), continues to strengthen its role of being a reliable partner to patients, healthcare professionals and customers, also during the coronavirus crisis.
In line with the company’s purpose of caring for people’s health as a trusted partner, its dedicated employees worked with great agility and persistence to keep supplying medicines, such as by raising production volumes significantly as the pandemic took hold in March.
To fulfil STADA’s purpose and act in line with the core value of Integrity, the main priority was caring for the health and safety of employees, their families and friends, and the company’s partners.
Despite the difficult operating environment created by the corona pandemic, which has reduced growth rates across the pharma industry, STADA showed a 16 per cent increase in reported Group sales to EUR 1.465 billion in the first half of 2020, with an organic sales growth of nine per cent.
Especially the second quarter was tough as markets saw sharp declines, particularly in countries in which patients typically pay out-of-pocket.
These declines were due to the Covid 19 outbreak leading to significantly fewer people and patients having visited pharmacies, doctors and hospitals, as well as the reversal of forward-buying. However, STADA’s comprehensive and diverse portfolio is, on the whole, standing up well to the challenging market conditions.
Included in the portfolio are the market-leading brands Zoflora®, Savlon®, Hedrin® and Covonia®, produced by the T&R team. Zoflora® is now the UK’s biggest selling household disinfectant brand and is currently being introduced into more markets internationally, bolstered by targeted line extensions and dedicated digital marketing campaigns.
In line with STADA’s strategy of portfolio acceleration, recent acquisitions – such as the former Takeda product portfolio in Russia and the CIS, Walmark with its consumer healthcare business in Central & Eastern Europe, the FERN-C brand in the Philippines – complemented the Group’s nine per cent organic sales growth. Integration of these acquisitions is progressing successfully.
STADA continues to evaluate a broad range of business-development opportunities, in line with fostering an entrepreneurial mindset. STADA is also investing in its production network, such as by expanding the centre of excellence for producing vitamins, minerals and supplements in Třnec, Czech Republic, that the company gained by acquiring Walmark.
EBITDA adjusted for special items rose by 14 per cent to EUR 337 million as STADA implemented ongoing efficiency measures, especially in production and in marketing and sales.
T&R UK executive vice-president Roger Scarlett-Smith said: “It is pleasing to see how STADA’s UK-based operations, such as the Thornton & Ross prescription and consumer healthcare business, the Nature’s Aid natural health unit and the Britannia Pharmaceuticals Parkinson’s disease specialist, have contributed to the group’s double-digit growth in the first half of this year. This has only been possible through the dedication and agility of all of our employees in the UK.”